[BCR-ABL转录的减半时间作为TKI治疗慢性髓性白血病患者深层分子反应的精确预测器]
Lan Yang1, Li-Xia Cao1, Hui-Juan Ren1
1Department of Hematology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot 010059, Inner Mongolia Autonomous Region, China.
Zhongguo shi yan xue ye xue za zhi
|October 31, 2024
概括
慢性髓性白血病 (CML) 治疗中的标记物BCR-ABL IS的减半时间 (HT) 预测了深度分子响应 (DMR). 将HT与BCR-ABLIS水平相结合,可以为接受氨酸激酶抑制剂治疗的CML患者提供准确的长期预测.
科学领域:
- 血液学 血液学 血液学
- 分子生物学分子生物学
- 在瘤学瘤学.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


